American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer

Rizzo, J. Douglas; Brouwers, Melissa; Hurley, Patricia A.; Seidenfeld, Jerome; Arcasoy, Murat O.; Spivak, Jerry L.; Bennett, Charles L.; Bohlius, Julia; Evanchuk, Darren M.; Goode, Matthew J.; Jakubowski, Ann A.; Regan, David H.; Somerfield, Mark R.

doi:10.1182/blood-2010-08-300541

Cited by 181 publications

(82 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, the most recent ESA label advises to prefer transfusions in patients with curative intent even at Hb levels between 8-10 g/dl, ignoring the known risks of transfusions in oncology [17,45]. Moreover, the drug label and current ASH/ASCO guidelines [28,42] generally recommend not to use ESA in patients with curative intent, although convincing data are lacking that transfusions carry a lower risk in this patient group than ESA. By contrast, several recent prospective randomised trials using ESA with curative intent did not provide evidence of an impact on survival or relapse in patients with Hodgkin's lymphoma [46], aggressive lymphoma [47], cervical cancer [48] and early breast cancer [49].…”

Section: Discussionmentioning

confidence: 99%

“…In the ASCO/ASH guideline version of 2008, evidence ‘that initiating ESAs at Hb levels > 10 g/dl either spares more patients from transfusion or substantially improves their quality of life' was considered not conclusive [26,41]. The most recent version still doubts the effect size for QoL change to be clinically meaningful and recommends ‘that the goal of ESA use should be to avoid transfusions without specific consideration of improvement in QoL as a target outcome' [28,42]. However, what should be the clinical aim of anaemia therapy, if not improving QoL?…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Treatment of Cancer-Associated Anaemia: Results from a Two-Day Cross-Sectional Survey in Germany

Schmitz

2013

Oncol Res Treat

View full text Add to dashboard Cite

Background: The aim was to re-evaluate the current prevalence and management of cancer-associated anaemia as defined by the World Health Organisation (WHO) and related risk factors. Patients and Methods: This was a prospective, 2-day web-based cross-sectional survey in cancer patients with non-myeloid malignancies in German outpatient clinics. Results: 89 centres collected data from 3,867 patients, of whom 74% received active cancer therapy. The median age was 65 years (range 19-99 years) and almost two-thirds were women; 68% of the patients had solid tumours (breast 34%, colorectal 17%, lung 8%), with 56% of them being metastatic; 73% had a WHO performance score of ≤ 1. The mean haemoglobin level was 12.0 ± 1.7 g/dl (± standard deviation; range 4.3-17.8 g/dl); the prevalence of levels below 12.0 g/dl was 49%. Two-thirds of these patients were not treated for anaemia; one-third received erythropoiesis-stimulating agents (12.6%), iron therapy (8.1%), transfusions (7.5%) or combinations thereof (8.0%) during the 4 weeks before evaluation. Chemotherapy, female sex, age and poor performance status were identified as significant anaemia-associated factors. Conclusions: The prevalence of untreated anaemia and the decreased performance status of cancer patients in Germany have hardly changed since the European Cancer Anaemia Survey (ECAS) in 2001. The treatment practice may not only be driven by guidelines and does not yet reflect new concepts of anaemia management.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Treatment of Cancer-Associated Anaemia: Results from a Two-Day Cross-Sectional Survey in Germany

Schmitz

2013

Oncol Res Treat

View full text Add to dashboard Cite

show abstract

“…27 The American Society of Hematology and the American Society of Clinical Oncology have proposed a clinical practice guideline on the use of EPO derivatives in patients with cancer. 28 HEPO may have an advantage in inhibiting tumor growth while preserving hematopoietic and tissue-protective effects.…”

Section: Discussionmentioning

confidence: 99%

A novel synthetic derivative of human erythropoietin designed to bind to glycosaminoglycans

Matsushima¹,

Toba²,

Hanawa³

et al. 2012

Drug Delivery

View full text Add to dashboard Cite

“…The outlier guideline on this subject has been the American Society of Hematology (ASH)/American Society of Clinical Oncology (ASCO), whose last anemia guideline was in 2010 and did not recommend the use of IV iron in CIA [8]. Unfortunately, the ASH/ASCO guideline has not been updated in many years.…”

Section: What Do Cancer Society Guidelines Recommend?mentioning

confidence: 99%

The Role of Intravenous Iron in the Treatment of Anemia Associated with Cancer and Chemotherapy

Rodgers

Gilreath

2019

Acta Haematol

View full text Add to dashboard Cite

Cancer-related anemia (CRA) is a commonly occurring problem for patients with cancer regardless of whether they are receiving treatment with chemotherapy or immunotherapy. It may result from one or more processes (decreased production, increased destruction, or increased loss of red blood cells, RBC). Perturbations in iron availability form the primary basis for anemia in many patients with cancer-related anemia. Functional iron deficiency (FID) anemia is a condition in which the patient has adequate or increased iron stores, but this iron pool is not available for erythropoiesis. Erythropoiesis-stimulating agents (ESAs) were the original treatment for FID; over time, however, if the supply of iron cannot keep pace with increased RBC synthesis driven by ESAs, FID may eventually lead to the lack or loss of ESA responsiveness. Subsequent clinical trials reported that intravenous (IV) iron could enhance the erythropoietic response to ESAs. This chapter reviews the pathogenesis of FID and summarizes the literature on the treatment of cancer- and chemotherapy-induced anemia. Clinical trials using IV iron with or without ESAs are reviewed in addition to the currently available IV iron products. The consensus conclusions from these trials, as well as guideline recommendations, support the use of IV iron in these patients to enhance ESA responsiveness, decrease ESA dosage, and reduce RBC transfusions. Little data have been published on the long-term safety of IV iron or its impact on tumor growth. This paper also briefly explores novel approaches for the treatment of FID anemia, which has relevance in treating not only cancer patients but also patients with benign inflammatory disorders.

show abstract

American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer

Cited by 181 publications

References 51 publications

Treatment of Cancer-Associated Anaemia: Results from a Two-Day Cross-Sectional Survey in Germany

Treatment of Cancer-Associated Anaemia: Results from a Two-Day Cross-Sectional Survey in Germany

A novel synthetic derivative of human erythropoietin designed to bind to glycosaminoglycans

The Role of Intravenous Iron in the Treatment of Anemia Associated with Cancer and Chemotherapy

Contact Info

Product

Resources

About